Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 7: zenagamtide once weekly versus insulin glargine once daily in type 2 diabetes with increased cardiovascular risk
2026-525209-11-00Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Small Molecules, Peptides
- Countries
- 16
01
Overview
Phase 3, randomised trial of amycretin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Change in haemoglobin A1c from baseline to week 52 and Time to first 4-point major adverse cardiovascular event. Planned start Sep 2026; status: withdrawn.
02
Drugs
amycretin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2026-525209-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525209-11-00.